Activity estimation in radioimmunotherapy using magnetic nanoparticles von Rasaneh, Samira, Rajabi, Hossein, Johari Daha, Fariba

Volltext

MRI contrast agent for molecular imaging of the HER2/neu receptor using targeted magnetic nanoparticles von Rasaneh, Samira, Rajabi, Hossein, Babaei, Mohammad Hossein, Akhlaghpoor, Shahram

Volltext

Development of DOTA-Rituximab to be Labeled with 90Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma von Johari Doha, Fariba, Rahmani, Siyavash, Rikhtechi, Pedram, Rasaneh, Samira, Sheikholislam, Zahra, Shahhosseini, Soraya

Volltext

Development of DOTA-Rituximab to be Labeled with 90 Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma von Johari Doha, Fariba, Rahmani, Siyavash, Rikhtechi, Pedram, Rasaneh, Samira, Sheikholislam, Zahra, Shahhosseini, Soraya

Volltext

Verification of Activity Accumulation Location Effect in Patients Treated with I-131 Radio Pharmacy on the Evaluated Exposure at Different Distances from Patient using NCAT Phantom von Kokhazadeh, Mahin, Rajabi, Hossein, Rasaneh, Samira, Askari, Mohammad ali, Taheri, Parisa

Volltext

Radiolabeling of Herceptin with 99mTc as a Her2 tracer von Samira Heydari, Hossein Rajabi, Samira Rasaneh, Fariba Johari Daha

Volltext

super(177)Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer von Rasaneh, Samira, Rajabi, Hossein, Babaei, Mohammad Hossein, Daha, Fariba Johari

Volltext

Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines von Rasaneh, Samira, Rajabi, Hossein, Hossein Babaei, Mohammad, Johari Daha, Fariba

Volltext

177 Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer von Rasaneh, Samira, Rajabi, Hossein, Babaei, Mohammad Hossein, Daha, Fariba Johari

Volltext

177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer von Rasaneh, Samira, Rajabi, Hossein, Babaei, Mohammad Hossein, Daha, Fariba Johari

Volltext

Radioimmunotherapy of mice bearing breast tumors with 177Lu-labeled trastuzumab von RASANEH, Samira, RAJABI, Hossein, AKHLAGHPOOR, Shahram, SHEYBANI, Shahab

Volltext

Synthesis and biodistribution studiesof 177Lu-trastuzumab as a therapeutic agent in the breast cancer mice model von Rasaneh, Samira, Rajabi, Hossein, Babaei, Mohammad Hossein, Johari Daha, Fariba

Volltext

Synthesis and biodistribution studiesof 177 Lu‐trastuzumab as a therapeutic agent in the breast cancer mice model von Rasaneh, Samira, Rajabi, Hossein, Babaei, Mohammad Hossein, Johari Daha, Fariba

Volltext

Synthesis and biodistribution studies of 177Lu-trastuzumab as a therapeutic agent in the breast cancer mice model von RASANEH, Samira, RAJABI, Hossein, MOHAMMAD HOSSEIN BABAEI, FARIBA JOHARI DAHA

Volltext

Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer von Rasaneh, Samira, Rajabi, Hossein, Babaei, Mohammad Hossein, Daha, Fariba Johari, Salouti, Mojtaba

Volltext

Radiolabeling of trastuzumab with super(177)Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer von Rasaneh, Samira, Rajabi, Hossein, Babaei, Mohammad Hossein, Daha, Fariba Johari, Salouti, Mojtaba

Volltext

Radiolabeling of trastuzumab with177 Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer von Rasaneh, Samira, Rajabi, Hossein, Babaei, Mohammad Hossein, Daha, Fariba Johari, Salouti, Mojtaba

Volltext

A new method for activity estimation in dosimetry of radiopharmaceuticals based on MRI imaging and magnetic nano particles von Rasaneh, Samira, Rajabi, Hossein, Babaei, Mohammad Hossein, Johari, Fariba, Sheybani, Shahab

Volltext

Radioimmunotherapy of the mice bearing breast tumor with Herceptin labeled ^sup 177^Lu von Rasaneh, Samira, Rajabi, Hossein, Babaei, Mohammad Hossein, Johari, Fariba, Sheybani, Shahab, Mirfallah, Seyed Hasan, Mazidi, Mohamad, Khoshbakht, Sepideh, Tavakoli, Yaser

Volltext